Patents Assigned to Lyvgen Biopharma Holdings Limited
  • BI-SPECIFIC ANTIBODIES COMPRISING ANTI-CD137 BINDING MOLECULES
    Publication number: 20230406950
    Abstract: Provided herein are antibodies binding to CD137 and bi-specific antibodies comprising such for targeting both CD137 and a second suitable antigen such as an immune checkpoint or modulator molecule. Examples include PD-1, PD-L1, GITR, CD40, or OX40. Also provided herein are therapeutic uses of such antibodies.
    Type: Application
    Filed: November 10, 2021
    Publication date: December 21, 2023
    Applicant: LYVGEN BIOPHARMA HOLDINGS LIMITED
    Inventors: Jieyi WANG, Yi WU
  • ANTI-CD40 BINDING MOLECULES AND BI-SPECIFIC ANTIBODIES COMPRISING SUCH
    Publication number: 20220372155
    Abstract: Provided herein are antibodies (e.g., humanized antibodies) binding to CD40 and bi-specific antibodies comprising such for targeting both CD40 and a second suitable antigen such as a tumor antigen or an immune checkpoint molecule. Examples of the second antigen include PD-1, PD-L1, HER2, B7H3, B7H4, netrotic tumor cells (TNT), or CEA. Also provided herein are therapeutic uses of such antibodies.
    Type: Application
    Filed: October 23, 2020
    Publication date: November 24, 2022
    Applicant: LYVGEN BIOPHARMA HOLDINGS LIMITED
    Inventors: Jieyi WANG, Yi WU
  • Anti-CD137 antibodies and uses thereof
    Patent number: 11505615
    Abstract: Disclosed herein are agonistic anti-CD137 antibodies and methods of using such for eliciting CD137 signaling, thereby enhancing immune responses such as T cell functions. The antibodies disclosed within may be used to treat diseases, such as cancer and immune disorders.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: November 22, 2022
    Assignee: Lyvgen Biopharma Holdings Limited
    Inventors: Jieyi Wang, Yi Wu
  • Humanized anti-CD137 antibodies and uses thereof
    Patent number: 11203643
    Abstract: Disclosed herein are humanized anti-CD137 antibodies and methods of using such for eliciting CD137 signaling, thereby enhancing immune responses such as T cell functions. The antibodies disclosed within may be used to treat diseases, such as cancer and immune disorders.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: December 21, 2021
    Assignee: LYVGEN BIOPHARMA HOLDINGS LIMITED
    Inventors: Jieyi Wang, Yi Wu
  • Anti-PD-1 antibodies and therapeutic uses thereof
    Patent number: 10913797
    Abstract: Anti-PD-1 antibodies and uses thereof in treating diseases associated with the PD-1 signaling, such as cancer, infectious diseases such as viral infection or immune related diseases.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: February 9, 2021
    Assignee: Lyvgen Biopharma Holdings Limited
    Inventors: Jieyi Wang, Liqun Dong, Yaolin Wang
  • THERAPEUTIC AGENTS AND METHODS FOR ENHANCING IMMUNE RESPONSES IN TUMOR MICROENVIRONMENT
    Publication number: 20200392227
    Abstract: Human IgG1, IgG2, and IgG4 mutants having mutations in the hinge domain and exhibiting altered binding activity to Fc? receptors such as Fc?RIIB (CD32B). Also provided herein are methods for selectively activating immune responses in a subject using a therapeutic agent capable of targeting both an immune cell surface receptor and Fc?RIIB.
    Type: Application
    Filed: March 28, 2018
    Publication date: December 17, 2020
    Applicant: LYVGEN BIOPHARMA HOLDINGS LIMITED
    Inventor: Jieyi WANG
  • ANTI-PD-1 ANTIBODIES AND THERAPEUTIC USES THEREOF
    Publication number: 20180346569
    Abstract: Anti-PD-1 antibodies and uses thereof in treating diseases associated with the PD-1 signaling, such as cancer, infectious diseases such as viral infection or immune related diseases.
    Type: Application
    Filed: November 17, 2016
    Publication date: December 6, 2018
    Applicant: Lyvgen Biopharma Holdings Limited
    Inventors: Jieyi Wang, Liqun Dong, Yaolin Wang